Skip to main content
. Author manuscript; available in PMC: 2022 Feb 12.
Published in final edited form as: JACC Heart Fail. 2020 Oct;8(10):800–810. doi: 10.1016/j.jchf.2020.06.020

Central Illustration: Effect of sacubitril/valsartan compared with enalapril on clinical, mechanistic and quality-of-life outcomes in patients with heart failure and reduced ejection fraction.

Central Illustration:

*Effect estimate is presented as a hazard ratio except for first and recurrent HF hospitalizations (rate ratio calculated using the negative-binomial method).

# Median systolic blood pressure at randomization = 120mmHg

† Median NT-proBNP at screening = 1,615pg/ml

Abbreviations: CV, cardiovascular; HF, heart failure; CI, confidence interval; ED, emergency department; HFrEF, heart failure and reduced ejection fraction; eGFR, estimated glomerular filtration rate; BP, blood pressure; NT-proBNP, N-terminal of the prohormone of B-type natriuretic peptide; cGMP, cyclic guanosine monophosphate; sST2, soluble suppression of tumorigenesis-2; LV, left ventricle; LA, left atrium; QOL, quality of life; NYHA, New York Heart Association.